(Reuters) – Pfizer Inc said on Tuesday that its chief scientific officer, Mikael Dolsten, a key figure behind the development of the company’s COVID-19 vaccine, would step down after a career spanning more than 15 years at the drugmaker.
The company said it would begin identifying a successor to Dolsten, a process expected to take several months.
Dolsten joined Pfizer as part of its acquisition of Wyeth in 2009, when he was named president of Worldwide Research and Development with responsibility for leading all of Pfizer’s research as well as the development of all of its treatments through mid-stage studies.
(Reporting by Christy Santhosh; Editing by Shilpi Majumdar)
